back to team members

Martin D. Madaus, PhD

Global Healthcare Executive


Dr. Martin D. Madaus is a serial global healthcare CEO, board member, investor and strategy consultant with over 30 years of experience in the Diagnostics and Life Science Tools Industry. He has a track record for delivering outstanding results by transforming large and complex business. He currently works for The Carlyle Group as an Operating Executive and serves as Chairman of Quanterix (NASDAQ: QTRX), Director of Repligen Corp. (NASDAQ: RGEN), Director at Azenta Life Sciences (NASDAQ: AZTA), and Director at Emulate Bio, Unchained Labs, and Syntis Bio.

He was Chairman and Chief Executive Officer at Ortho-Clinical Diagnostics, Inc. (OCD) from June 2015 until February of 2019 leading the carve-out from JNJ and the business turnaround.

Prior to joining Ortho, Dr. Madaus served as Executive Chairman of Quanterix Corporation, and as Senior Healthcare Advisor to the Carlyle Group.

He was Chairman, President and Chief Executive Officer of Millipore Corporation (NYSE: MIL) from January 2005 to July 2010. In addition, Dr. Madaus was President and Chief Executive Officer of Roche Diagnostics Corporation North America from 2000 to 2004.

Dr. Madaus started his career in the Diagnostics Industry in 1989 at Boehringer Mannheim, Germany and served in various product management, marketing and general management roles in Germany, the United States and Canada.

Dr. Madaus has extensive public and private company board experience and has served on the board of Mettler-Toledo International Inc. (NYSE: MTD), Covidien PLC (NYSE: COV), Millipore (NYSE:MIL), PPD International, Quanterix (NASDAQ: QTRX).

Dr. Madaus received a Doctor of Veterinary Medicine degree from the University of Munich in Germany and a PhD in Veterinary Medicine from the Veterinary School of Hanover in Germany.